Abstract Body

To explore the association between hormonal contraceptive use and antiretroviral therapy (ART) effectiveness and genital HIV shedding among HIV-positive women on ART.

We analyzed plasma viral load and genital viral RNA shedding from 1,079 HIV-positive women initiating ART who were followed prospectively in three HIV prevention studies in sub-Saharan Africa. Plasma and endocervical swab samples were collected every six months. Self-reported contraceptive use was categorized into injectable, implant, oral, or non-hormonal/no contraception. We used multivariate Cox regression to assess time to plasma viral suppression and logistic regression with generalized estimating equations to assess genital viral shedding for each contraceptive method.

At the time of ART initiation, there were 211 (20%) injectable, 69 (6%) implant, 50 (5%) oral, and 749 (69%) non-hormonal or no method users. Viral suppression was high (90% by 6 months) and hormonal contraceptives did not significantly diminish time to viral suppression as compared to non-hormonal or no methods [adjusted hazard ratios were: injectables 0.89 (95% CI 0.75-1.1), implants 0.91 (0.68-1.2), and oral methods 1.3 (1.1-1.7)]. Genital viral shedding at any time after ART initiation was uncommon (only 9% of samples had detectable viral shedding) and hormonal contraceptives were not significantly associated with changes in detection of genital viral shedding [adjusted odds ratios were: injectables 1.1 (0.73-1.7), implants 0.67 (0.30-1.5), and oral methods 0.55 (0.18-1.6)].

Hormonal contraceptive use was not significantly associated with reduced ART effectiveness or increased genital HIV shedding among HIV-positive women on ART. HIV-positive women should continue to be offered the full range of contraceptive options that best meet their needs.